Back to Search
Start Over
The emerging role of lncRNA MEG3 and MEG3 rs7158663 in hepatocellular carcinoma.
- Source :
- European Review for Medical & Pharmacological Sciences; 2022, Vol. 26 Issue 1, p11-21, 11p
- Publication Year :
- 2022
-
Abstract
- OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy in Egypt. Genetic and environmental factors play a role in its development. This study explored the association between the long non-coding RNA (lncRNA) MEG3 rs7158663 polymorphism, MEG3 expression, and the risk of HCC and other clinicopathologic characteristics in an Egyptian population. PATIENTS AND METHODS: This case-control study included 114 patients with HCC and 110 healthy controls. TaqMan Real-time PCR was used to analyze lncRNA MEG3 rs7158663. Serum MEG3 expression levels were measured using RT-PCR. RESULTS: The AA, GA+AA, and A alleles were associated with increased risk for HCC (adjusted odds ratio (OR) 11.84%, 95% CI 4.07-34.45, p < 0.0001; adjusted OR 3.18, 95% CI 1.79-5.67, p < 0.0001; and adjusted OR 2.87, 95% CI 1.91-4.34, p < 0.0001, respectively). The mutant genotype and allele were linked to an increased risk in male patients and patients ≥ 50 years old. MEG3 serum expression level was downregulated in HCC patients. The rs7158663 G > A polymorphism and downregulated MEG3 were significantly associated with larger tumor size and advanced disease stage. CONCLUSIONS: MEG3 rs7158663 single nucleotide polymorphisms and downregulated lncRNA MEG3 were associated with HCC risk and may represent diagnostic and bad prognostic factors for HCC patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 11283602
- Volume :
- 26
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- European Review for Medical & Pharmacological Sciences
- Publication Type :
- Academic Journal
- Accession number :
- 154780300